美国丹娜-法伯癌症研究所Toni K. Choueiri、纪念斯隆-凯特琳癌症中心Robert J. Motzer等研究人员合作报道了avelumab+阿西替尼与舒尼替尼在治疗晚期肾细胞癌中的比较。相关论文于2020年9月7日在线发表在《自然—医学》杂志上。
Title: Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Author: Robert J. Motzer, Paul B. Robbins, Thomas Powles, Laurence Albiges, John B. Haanen, James Larkin, Xinmeng Jasmine Mu, Keith A. Ching, Motohide Uemura, Sumanta K. Pal, Boris Alekseev, Gwenaelle Gravis, Matthew T. Campbell, Konstantin Penkov, Jae Lyun Lee, Subramanian Hariharan, Xiao Wang, Weidong Zhang, Jing Wang, Aleksander Chudnovsky, Alessandra di Pietro, Amber C. Donahue, Toni K. Choueiri
Abstract: We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial (n=886; NCT02684006), which demonstrated significantly prolonged progression-free survival (PFS) with first-line avelumab+axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We found that neither expression of the commonly assessed biomarker programmed cell death ligand 1 (PD-L1) nor tumor mutational burden differentiated PFS in either study arm. Similarly, the presence of FcR single nucleotide polymorphisms was unimpactful. We identified important biological features associated with differential PFS between the treatment arms, including new immunomodulatory and angiogenesis gene expression signatures (GESs), previously undescribed mutational profiles and their corresponding GESs, and several HLA types. These findings provide insight into the determinants of response to combined PD-1/PD-L1 and angiogenic pathway inhibition and may aid in the development of strategies for improved patient care in aRCC.